Publications

C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
Klümper N, Sikic D, Saal J, Büttner T, Goldschmidt F, Jarczyk J, Becker P, Zeuschner P, Weinke M, Kalogirou C, Breyer J, Burger M, Nuhn P, Tully K, Roghmann F, Bolenz C, Zengerling F, Wirtz RM, Muders M, Kristiansen G, Bald T, Ellinger J, Wullich B, Hölzel M, Hartmann A, Erben P, Ritter M, Eckstein M. Eur J Cancer. 2022 May;167:13-22. doi: 10.1016/j.ejca.2022.02.022. Epub 2022 Mar 30. PMID: 35366569

(A) Distribution of baseline CRP across different CRP kinetics groups. (B) Distribution of PD-L1 expression across CRP kinetics groups assessed as combined positivity score (CPS). The dashed line indicates CPS of 10% as a threshold for first-line pembrolizumab therapy in cisplatin-ineligible mUC. (C) Distribution of best RECIST-based response across CRP kinetics groups (PR = partial remission, CR = complete remission, SD = stable disease, PD = progressive disease).

Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
Mayr R, Eckstein M, Wirtz RM, Santiago-Walker A, Baig M, Sundaram R, Carcione JC, Stoehr R, Hartmann A, Bolenz C, Burger M, Otto W, Erben P, Breyer J. Eur Urol. 2022 Mar 26:S0302-2838(22)01670-0. doi: 10.1016/j.eururo.2022.02.028. Online ahead of print. PMID: 35351346

Correlation (A) between FGFR3 alterations (mutations, fusions, and amplifications) and FGFR3 mRNA expression, and (B) between specific FGFR3 mutations and FGFR3 mRNA expression. FGFR = fibroblast growth factor receptor.

High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer.
Sikic D, Eckstein M, Weyerer V, Kubon J, Breyer J, Roghmann F, Kunath F, Keck B, Erben P, Hartmann A, Wirtz RM, Wullich B, Taubert H, Wach S. Urol Oncol. 2022 Feb;40(2):63.e9-63.e18. doi: 10.1016/j.urolonc.2021.06.021. Epub 2021 Jul 28. PMID: 34330652

Recurrence-free survival (RFS) based on the mRNA expression of ESR2 A, ERBB2 B in the total cohort. High expression of markers leads to reduced RFS.

Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy.

Sikic D, Weyerer V, Geppert CI, Bertz S, Lange F, Taubert H, Wach S, Schmitz-Draeger BJ, Wullich B, Hartmann A, Eckstein M.
Urol Oncol. 2021 Aug 20:S1078-1439(21)00343-4. doi: 10.1016/j.urolonc.2021.07.025.

Färbungen an Blasenkarzinom Schnitten mit Haematoxilin Eosin (HE) mit verschiedenen Anteilen stromaler Tumor infiltrierender Lymphozyten (sTILs, Bildvergrößerung 220x).

The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer

Sikic D, Taubert H, Breyer J, Eckstein M, Weyerer V, Keck B, Kubon J, Otto W, Worst TS, Kriegmair MC, Erben P, Hartmann A, Wullich B, Wirtz RM, Wach S.
Cancer Manag Res. 2021 Aug 20;13:6567-6578. doi: 10.2147/CMAR.S318893. eCollection 2021.
PMID: 34447272 Free PMC article.

Kaplan-Meier Analyse von FGFR3 mRNA Expression in Bezug auf das RFS bei Patienten ohne postoperative Instillationstherapie (A) und Patienten mit postoperativer Instillationstherapie (B).

Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients.

Eckstein M, Lieb V, Jung R, Sikic D, Weigelt K, Stöhr R, Geppert C, Weyerer V, Bertz S, Serrero G, Yue B, Hartmann A, Wullich B, Taubert H, Wach S.
Cells. 2021 Jul 15;10(7):1796. doi: 10.3390/cells10071796.
PMID: 34359965 Free PMC article.

Immunhistochemische Färbung von GP88 von Tumorzellen und Immunzellen (A: Tumorzellen positiv, Immunzellen negativ); (B: Immunzellen positiv; Tumorzellen negativ); (C: Immunzellen und Tumorzellen negativ)

High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
Sikic D, Taubert H, Wirtz RM, Breyer J, Eckstein M, Weyerer V, Kubon J, Erben P, Bolenz C, Burger M, Hartmann A, Wullich B, Wach S, Keck B. Life (Basel). 2021 Jun 30;11(7):642. doi: 10.3390/life11070642. PMID: 34209360

Kaplan–Meier analyses: Association of AR mRNA expression with OS, CSS and RFS. High AR mRNA expression was associated with improved OS (p = 0.015) and CSS (p = 0.020) and tended to be associated with better RFS (p = 0.051).

Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients.

Weyerer V, Strissel PL, Strick R, Sikic D, Geppert CI, Bertz S, Lange F, Taubert H, Wach S, Breyer J, Bolenz C, Erben P, Schmitz-Draeger BJ, Wullich B, Hartmann A, Eckstein M.
Cancers (Basel). 2021 May 12;13(10):2327. doi: 10.3390/cancers13102327.
PMID: 34066058 Free PMC article.

Übereinstimmung von verschiedenen PD-L1 scoring algorithmen und cut-off systemen

KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.
Jütte H, Reike M, Wirtz RM, Kriegmair M, Erben P, Tully K, Weyerer V, Eckstein M, Hartmann A, Eidt S, Wezel F, Bolenz C, Tannapfel A, Noldus J, Roghmann F. J Pers Med. 2021 May 26;11(6):473. doi: 10.3390/jpm11060473. PMID: 34073233

(A) KRT5, (B) KRT20 mRNA expression (ΔCT) in MIBC patients before (blue) and after neoadjuvant chemotherapy (post NAC in orange). KRT20 expression decreases significantly after NAC.

Neuropilin-2 and Its Transcript Variants Correlate with Clinical Outcome in Bladder Cancer.

Förster S, Givehchi M, Nitschke K, Mayr T, Kilian K, Dutta S, Datta K, Nuhn P, Popovic Z, Muders MH, Erben P.
Genes (Basel). 2021 Apr 9;12(4):550. doi: 10.3390/genes12040550.
PMID: 33918816 Free PMC article.

Kaplan-Meier Analyse des Gesamtüberlebens stratifiziert nach NRP2 mRNA und seiner Transkripte (A-C) und NRP1, PDGFC; PDGFD (D, E, F).

Quality assessment of radical cystectomy-opportunities, risks, challenges.

Roghmann F, Breyer J, Kriegmair M, Wezel F, Burger M, Noldus J, Bolenz C; Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium e. V..
Urologe A. 2021 Feb;60(2):151-161. doi: 10.1007/s00120-020-01439-8. Epub 2021 Jan 22.
PMID: 33481063 Review. German.

Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy.

Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz R, Pfannstiel C, Wullweber A, Lange F, Erben P, Stoehr R, Bertz S, Geppert CI, Fuhrich N, Taubert H, Wach S, Breyer J, Otto W, Burger M, Bolenz C, Keck B, Wullich B, Hartmann A, Sikic D; BRIDGE Consortium e.V., Mannheim, Germany.
J Immunother Cancer. 2020 May;8(1):e000162. doi: 10.1136/jitc-2019-000162.
PMID: 32448798 Free PMC article.

The Tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes

Pfannstiel C, Strissel PL, Chiappinelli B, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst TS, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert C, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M
Cancer Immunol Res. 2019 Jun;7(6):923‐938.
DOI: 10.1158/2326-6066.CIR-18-0758
PMID: 30988029

Androgen Receptor mRNA expression in urothelial carcinoma of the bladder: a retrospective analysis of two independent cohorts

Sikic D, Wirtz RM, Wach S, Dyrskjot L, Erben P, Bolenz C, Breyer J, Otto W, Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B
Transl Oncol. 2019 Apr;12(4):661-668.
DOI: 10.1016/j.tranon.2019.01.005
PMID: 30831560

Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder

Erben P, Sikic D, Wirtz RM, Martini T, Weis CA, Breyer J, Otto W, Keck B, Hartmann A, Bolenz C
Virchows Arch. 2019 Feb;474(29, 209-217.
DOI: 10.1007/s00428-018-2496-9
PMID: 30483954

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F
Eur J Cancer. 2019 Jan;106:234-243.
DOI: 10.1016/j.ejca.2018.11.007
PMID: 30528808

Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy

Martini T, Heinkele J, Mayr R, Weis CA, Wezel F, Wahby S, Eckstein M, Schnöller T, Breyer J, Wirtz R, Ritter M, Bolenz C, Erben P
Urol Oncol. 2018 Dec;36(12):530.e19-530.e27.
DOI: 10.1016/j.urolonc.2018.09.003
PMID: 3044644

Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer.

Eckstein M, Sikic D, Strissel PL, Erlmeier F; BRIDGE Consortium Germany.
Eur Urol. 2018 Oct;74(4):527-529. doi: 10.1016/j.eururo.2018.06.028. Epub 2018 Jul 12.
PMID: 30007816 No abstract available.

mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants

Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Porubsky S, Hartmann A, Erben P
Int J Mol Sci. 2018 Oct 30;19(11):3396.
DOI: 10.3390/ijms19113396
PMID: 30380731

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making

Worst TS, Weis CA, Stöhr R, Bertz S, Eckstein M, Otto W, Breyer J, Hartmann A, Bolenz C, Wirtz RM, Erben P
Sci Rep. 2018 Sept 26;8(1):14383.
DOI: 10.1038/s41598-018-32569-x
PMID: 30258198

High CDKN2A/p16 and low FGFR3 expression predict progressive potential of stage pT1 urothelial bladder carcinoma

Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W
Clin Genitourin Cancer. 2018 Aug;16(4),248-256e2.
DOI: 10.1016/j.clgc.2018.01.009
PMID: 29525349

Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer.

Otto W, van Rhijn BW, Breyer J, Bertz S, Eckstein M, Mayr R, Lausenmeyer EM, Denzinger S, Burger M, Hartmann A
Int J Urol. 2018 May;25(5):442-449.
DOI: 29473226

Prognostic Value of molecular breast cancer subtypes based on Her2, PGR and Ki67 mRNA-Expression in muscle invasive bladder cancer

Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P
Transl Oncol. 2018 Apr;11(2):467-476.
DOI: 10.1016/j.tranon.2018.02.001
PMID: 29477637

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients

Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A
Cancer Immunol Immunother. 2018 Mar;67(3):403-412.
DOI: 10.1007/s00262-017-2093-9
PMID: 29150702

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P
Oncotarget. 2018 Feb;19;9(19):15001-15014.
DOI: 10.18632/oncotarget.24531
PMID: 29599921

FOXM1 predicts overall and diseases specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes

Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, Otto W, Bolenz C, Hartmann A, Erben P
Oncotarget. 2017 Jul 18;8(29):47595-47606.
DOI: 10.18632/oncotarget.17394
PMID: 28498805

Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin-fixed TUR biopsies.

Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A
Oncotarget. 2017 Jun 28;8(40):67684-67695.
DOI: 10.18632/oncotarget.18804
PMID: 28978063

Immunohistochemical subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis

Sikic D, Keck B, Wach S, Taubert H, Wullich B, Goebell PJ, Kahlmeyer A, Olbert P, Isfort P, Nimphius W, Hartmann A, Giedl J
PLoS One. 2017 Jun 20;12(6):e0179602.
DOI: 10.1371/journal.pone.0179602
PMID: 28632777

High androgen receptor mRNA expression is independently associated with prolonged cancer-specific and recurrence-free survival in stage T1 bladder cancer

Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stoehr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W
Trans Oncol. 2017 Jun;10(3):340-345.
DOI: 10.1016/j.tranon.2017.01.013
PMID: 28342317

In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival

Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A
Virchows Arch. 2017 Mar;470(3):267-274.
DOI: 10.1007/s00428-017-2064-8
PMID: 28074276

ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ

Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A
Urol Int. 2017;98(3):282-289.
DOI: 10.1159/000453670
PMID: 27992871

ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).

Breyer J, Wirtz RM, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A, Otto W
Virchows Arch. 2016 Nov;469(5):547-552.
DOI: 10.1007/s00428-016-2002-1
PMID: 27514658

Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer

Kriegmair MC, Balk M, Wirtz R, Steidler A, Weis CA, Breyer J, Hartmann A, Bolenz C, Erben P
Anticancer Res. 2016 Oct;36(10):5205-5213.
DOI: 10.21873/anticanres.11091
PMID: 27798881

Molekulare Klassifikation des Harnblasenkarzinoms – Mögliche Ähnlichkeit zum Mammakarzinom

Wirtz RM, Fritz V, Stöhr R, Hartmann A
Pathologe. 2016 Feb;37(1):52-60.
DOI: 10.1007/s00292-015-0134-8
PMID: 26780243